These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26951928)

  • 1. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
    Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
    Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor effects of hTRAIL by binding to endogenous albumin.
    Park K
    J Control Release; 2016 Apr; 228():206. PubMed ID: 27064072
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted Delivery to Tumor-associated Pericytes via an Affibody with High Affinity for PDGFRβ Enhances the
    Tao Z; Yang H; Shi Q; Fan Q; Wan L; Lu X
    Theranostics; 2017; 7(8):2261-2276. PubMed ID: 28740549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.
    Su T; Yang H; Fan Q; Jia D; Tao Z; Wan L; Lu X
    Int J Pharm; 2016 Feb; 499(1-2):195-204. PubMed ID: 26752086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and characterization of a novel variant of human tumor necrosis factor-related apoptosis-inducing ligand from the rhesus monkey, Macaca mulatta.
    Jia D; Yang H; Tao Z; Wan L; Cheng J; Lu X
    Appl Microbiol Biotechnol; 2016 Apr; 100(7):3035-47. PubMed ID: 26610804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution.
    Kim TH; Jiang HH; Youn YS; Park CW; Lim SM; Jin CH; Tak KK; Lee HS; Lee KC
    J Pharm Sci; 2011 Feb; 100(2):482-91. PubMed ID: 20669330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 11. Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
    Zhang J; Bodenko V; Larkina M; Bezverkhniaia E; Xu T; Liao Y; Abouzayed A; Plotnikov E; Tretyakova M; Yuldasheva F; Belousov MV; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2024 Jun; 370():468-478. PubMed ID: 38697314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.
    Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z
    Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo.
    Tao Z; Liu Y; Yang H; Feng Y; Li H; Shi Q; Li S; Cheng J; Lu X
    Biomacromolecules; 2020 Oct; 21(10):4017-4029. PubMed ID: 32804484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
    Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
    Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior serum half life of albumin tagged TNF ligands.
    Müller N; Schneider B; Pfizenmaier K; Wajant H
    Biochem Biophys Res Commun; 2010 Jun; 396(4):793-9. PubMed ID: 20447380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial.
    Jiang J; Liu X; Deng L; Zhang P; Wang G; Wang S; Liu H; Su Y
    Eur J Pharmacol; 2014 Oct; 740():722-32. PubMed ID: 24929054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
    Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
    Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDGFRβ-targeted TRAIL specifically induces apoptosis of activated hepatic stellate cells and ameliorates liver fibrosis.
    Li R; Li Z; Feng Y; Yang H; Shi Q; Tao Z; Cheng J; Lu X
    Apoptosis; 2020 Feb; 25(1-2):105-119. PubMed ID: 31894448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer.
    Han L; Huang R; Li J; Liu S; Huang S; Jiang C
    Biomaterials; 2011 Feb; 32(4):1242-52. PubMed ID: 20971503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conjugation to 10 kDa Linear PEG Extends Serum Half-Life and Preserves the Receptor-Binding Ability of mmTRAIL with Minimal Stimulation of PEG-Specific Antibodies.
    Nie Q; Jia D; Yang H; Feng Y; Fan Q; Shi Q; Wan L; Lu X
    Mol Pharm; 2017 Feb; 14(2):502-512. PubMed ID: 28029256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.